Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in shareholdings.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific transaction rather than a financial performance report.
Material Changes
The material change disclosed is an increase in the holding of Ordinary Shares by a connected person, Dr. S Dexter, following the re-investment of a dividend paid on October 3, 2013, and a subsequent purchase of shares on October 4, 2013.
Outlook, Risks, and Unusual Items
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The transaction was executed at a price of 1561.8039 pence per share and was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: October 4, 2013 (purchase); October 3, 2013 (dividend reinvestment).
- Connected Person: Dr. S Dexter (Connected to Director Dr. P J T Vallance).
- Shares Acquired: 143 Ordinary Shares.
- Transaction Price: 1561.8039 pence per share.
- Notification Date: October 14, 2013.